Live-0ΔNLS vaccine elicits a stronger IgG antibody response than UV-0ΔNLS vaccine.

<p><b>(A)</b> Mean ± sem neutralizing antibody titer in pre-challenge (Day 60) serum collected from C57BL/10 mice immunized with mock versus UV-0ΔNLS or live-0ΔNLS vaccines (n = 16 per group). <b>(B)</b> Mean ± sem total HSV-2-specific IgG levels in pre-challenge serum, as determined by a flow cytometry-based ABVIC (antibody-binding to virus-infected cell) assay comparing the mean fluorescent intensity of IgG antibody bound to uninfected versus HSV-2-infected test cells (n = 16 per group). Mouse antibody-labeled test cells were secondarily labeled with APC-conjugated antibody specific for total IgG, IgG subclass 1, or IgG subclass 2. Double asterisks (**) denote p < 0.001 that neutralizing antibody or HSV-2⁺ cell-specific antibody levels were equivalent between live 0ΔNLS and UV-0ΔNLS-immunized mice, or mock-immunized mice, as determined by one-way ANOVA and Tukey's post-hoc-test.